These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead

Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.

10/15/2026, 3:14 PM • The Motley Fool

Alibaba vs. Coupang: Which E-Commerce Giant Is a Better Buy in 2026?

The article compares Alibaba and Coupang as investment opportunities in 2026. Alibaba, despite facing regulatory uncertainty, AI spending pressures, and geopolitical risks, is recommended as the better buy due to its stronger profitability (10.1% net margin), attractive valuation (16.9x forward P/E), and double-digit AI cloud revenue growth. Coupang, while growing faster (14.1% YoY revenue growth), faces record regulatory fines, perjury investigations, and shareholder lawsuits with a thin 0.6% net margin, making it a riskier choice.

10/15/2026, 2:29 PM • The Motley Fool

Fantastic News for Marvell Stock Investors

Marvell Technology has surged 205% this year by capitalizing on AI infrastructure demand with custom chips. At its investor day, the company raised fiscal 2028 revenue guidance to $20 billion and projects $70-90 billion by fiscal 2031, with data center segment growing 55-70% annually. Despite a high 63.3x forward earnings multiple, the stock remains attractive given strong demand signals from hyperscalers and partnerships like Amazon's Trainium chip program.

10/15/2026, 11:38 AM • The Motley Fool

Here's What $5,000 Invested in Nvidia Stock Could Be Worth by the End of 2030

Nvidia is positioned as a leader in AI infrastructure with strong growth potential through 2030. Analyst projections suggest a $5,000 investment (approximately 22 shares) could grow to $9,500-$12,650 by end of 2029, with more aggressive models projecting $13,640-$18,260 by fiscal 2031, representing 90-270% upside. The company benefits from continued AI capex spending, predictable GPU replacement cycles, and potential for earnings-per-share growth, though risks include AI spending slowdowns and increased competition from custom silicon.

10/15/2026, 10:58 AM • The Motley Fool

Coupang vs. Uber Technologies: Decelerating Versus Steady Revenue Growth

Uber Technologies demonstrates stronger revenue performance with consistent 27% growth over two years and improving operating margins, while Coupang faces slowing revenue growth, regulatory challenges, and negative operating margins. Uber's global platform across 70+ countries and autonomous vehicle partnerships position it favorably compared to Coupang's South Korea-focused e-commerce business, though both face litigation risks.

10/15/2026, 10:44 AM • The Motley Fool

Figma vs. Palantir Technologies: Which Technology Stock Is a Better Buy in 2026?

The article compares Figma and Palantir Technologies as investment options in 2026. Palantir is recommended as the stronger choice, posting 150% U.S. commercial revenue growth in Q2 2026 with profitability and raised guidance, while Figma, despite strong revenue growth, saw its stock drop 16% after earnings due to heavy AI investment costs compressing margins and widening operating losses.

10/15/2026, 10:37 AM • The Motley Fool

The Stock Market Will Look Completely Different by 2030. This Is the Stock I'm Buying Before It Does.

As AI adoption shifts from infrastructure building to productivity gains, Synopsys emerges as a potential winner by providing chip design software and IP. The company targets $17 billion in revenue and $8.5 billion in operating income by fiscal 2030, but valuation risks could limit shareholder returns despite strong earnings growth projections.

10/15/2026, 9:45 AM • The Motley Fool

Here's What a $10,000 Investment in IonQ Could Be Worth by October 2027

IonQ, a pure-play quantum computing company, has seen its stock drop 57% over the past 12 months despite strong revenue growth of 287% year-over-year. While analysts are optimistic with a median price target of $65 (potentially turning $10,000 into $18,146), the company remains unprofitable with rapidly growing losses. The article suggests IonQ could benefit from mainstream quantum computing adoption but recommends only small, speculative positions due to high volatility and the technology's early stage.

10/15/2026, 7:20 AM • The Motley Fool

Big Tech Will Spend $745 Billion on AI This Year. These Stocks Get Paid on Every Dollar.

Amazon, Alphabet, Microsoft, and Meta are projected to spend $745 billion on capital expenditures this year, primarily for data center infrastructure. Hardware suppliers Nvidia, Broadcom, and Arista Networks are positioned to benefit from this spending through GPU sales, custom AI chips, and networking equipment. Nvidia trades at an attractive 14x forward P/E, Broadcom at 18x with strong AI revenue growth projections, while Arista commands a premium 38x valuation despite deployment risks.

10/15/2026, 7:10 AM • The Motley Fool

Not Memory. Not Energy. This Is the Biggest Bottleneck in Artificial Intelligence, and These Are the Companies That Can Benefit.

Capital constraints, not chip supply, represent the biggest bottleneck for AI data center expansion. Major hyperscalers like Alphabet, Amazon, and Meta face negative free cash flow as they scale AI spending. Custom silicon (XPUs) offer a solution by reducing upfront costs, positioning XPU makers like Broadcom and Marvell as major beneficiaries of this shift.

10/15/2026, 4:14 AM • The Motley Fool

The Stock Market Is Echoing a Warning From the Dot-Com Bubble, and History Says Investors Should Make This 1 Move

The S&P 500 has gained 100% over four years driven by AI enthusiasm, but the Buffett indicator—which measures total U.S. stock market value relative to GDP—has reached a historic high of 238%, surpassing dot-com bubble levels of 148%. This suggests stocks are overvalued relative to economic fundamentals. However, history shows that despite past market declines following similar peaks, the market has always recovered and delivered long-term gains, suggesting investors should maintain positions rather than sell.

10/15/2026, 4:10 AM • The Motley Fool

Author A. Nobody Publishes London Superhero Thriller Under His Hero's Own Name

A London-based novelist publishing under the pseudonym 'A. Nobody' has released a thriller novel about a masked vigilante who stops crimes across London while remaining anonymous. The author has mirrored their protagonist by publishing without a public profile, using only the pen name. The book, independently published on March 2, 2026, explores themes of heroism without recognition and critiques influencer culture, with London as both setting and subject.

10/14/2026, 8:58 PM • GlobeNewswire

Prediction: UPS Will Miss Estimates (but the Stock Could Still Be a Good Value)

UPS faces headwinds from elevated fuel costs, Amazon's new supply chain services, and declining e-commerce demand, which could lead to missed earnings estimates in Q3 2026. However, the stock's high dividend yield and market expectations of a miss may position it for recovery if the company merely meets expectations. The dividend sustainability remains a concern despite the potential value opportunity.

10/14/2026, 6:05 PM • The Motley Fool

Jim Cramer Calls CoreWeave the "Real Deal," but the Stock Crashed 15% the Very Next Day. Should You Buy the Dip?

Jim Cramer endorsed CoreWeave as the only AI neocloud he trusts, but the stock plunged 15% the next day after venture capitalist Chamath Palihapitiya highlighted concerns about the company's soaring debt levels. CoreWeave faces significant financial risks with $51.6 billion in total debt obligations and projected negative free cash flow of $25-28 billion annually through 2028, raising questions about whether strong customer demand can offset the company's aggressive borrowing strategy.

10/14/2026, 5:30 PM • The Motley Fool

Microsoft Just Unveiled a Brand-New AI Chip. Could It Be the "Nvidia Killer" Everyone's Been Looking For?

Microsoft unveiled its Maia 300 AI chip, claiming 40% better token processing per megawatt than GPUs. Rather than competing on raw power where Nvidia dominates, Microsoft is targeting cost efficiency for AI inference workloads. The chip signals a shift in the AI industry from pure performance competition toward optimizing economics and cost-per-token delivery, though Nvidia's high-end processors remain critical to Microsoft's AI strategy.

10/14/2026, 4:57 PM • The Motley Fool